You are viewing: UK Gene Editing Market analysis
Part of: Gene Editing Market (Global)

The UK Gene Editing Market was valued at $80.6 Million in 2024 and projected to reach to $162.1 Million by 2029, representing a compound annual growth rate of 15.0%. The UK gene editing market is poised for substantial expansion driven by its advanced healthcare infrastructure, world-class research capabilities, and supportive regulatory environment.

UK Gene Editing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Gene Editing Market Trends and Insights

  • The UK's advanced healthcare infrastructure, strong regulatory framework, and significant investment in biotechnology research are driving expansion in gene editing technologies and therapies.
  • The UK's position as a leading life sciences hub in Europe supports accelerated adoption of CRISPR, base editing, and prime editing platforms across therapeutic and research applications. The UK gene editing market is expanding at a 15.0% compound annual growth rate, outpacing global trends.
  • The UK's commitment to precision medicine, coupled with substantial government funding for genomic research and a robust clinical trial ecosystem, positions the country as a key innovation center.
  • By 2029, the UK gene editing market is expected to double in value, reflecting increasing commercialization of gene-edited therapies and growing demand for advanced molecular tools in the UK's pharmaceutical and biotech sectors..

Key Market Statistics

  • CAGR (2024-2029) 15.0% CAGR
  • Market Size, 2024 ~USD 80.6 Million
  • Forecast, 2029 ~USD 162.1 Million
  • Country UK

UK Gene Editing Market Overview

Market Valuation Growth :

The UK gene editing market is valued at $80.6 million in 2024, with a projected CAGR of 15% through 2029, reaching $162.1 million. This growth rate significantly outpaces the global average of 10.2%, positioning the UK as a high-growth market within Europe.

Regulatory Leadership :

The UK's robust regulatory framework and post-Brexit autonomy enable faster approval pathways for gene editing therapies. The MHRA's streamlined processes and the UK's membership in international regulatory harmonization initiatives support accelerated commercialization of innovative treatments.

Research & Innovation Hub :

The UK hosts world-leading research institutions including the Francis Crick Institute, Wellcome Trust, and numerous university biotech clusters. Significant government funding through UK Research and Innovation (UKRI) and private sector investment drive cutting-edge gene editing development and clinical applications.

NHS Integration Opportunities :

The National Health Service's commitment to adopting advanced therapies creates substantial opportunities for gene editing solutions. NHS England's gene therapy commissioning framework and rare disease initiatives provide clear pathways for market penetration and reimbursement.

UK Gene Editing Market Dynamics

  • Investment in life sciences infrastructure, coupled with the government's Life Sciences Vision, positions the UK as a premier destination for gene editing innovation and commercialization.
  • The NHS's increasing adoption of gene therapies and the presence of leading biotech companies create a dynamic ecosystem for market growth. Key growth drivers include rising prevalence of genetic disorders, increasing clinical trial activity, and growing private sector investment in gene editing startups.
  • The UK's competitive advantages in regulatory approval timelines and research funding will continue attracting international biotech companies and venture capital.
  • By 2029, the market is expected to nearly double, reflecting strong demand for therapeutic applications and expanding treatment indications across rare and common genetic diseases..

Market Ecosystem

logo-mobile

GENE EDITING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Collaborates with Beam Therapeutics to develop in vivo base editing therapies targeting rare genetic diseases affecting the liver, muscles, and central nervous system. The programs utilize precision genome editing and lipid nanoparticle-based delivery technologies. Supports the development of targeted genetic medicines, enables precise modification of disease-associated DNA sequences, and advances research into potential treatments for inherited disorders.
company logo
Supports genome editing research through its Somatic Cell Genome Editing (SCGE) program, focusing on CRISPR-based technologies, targeted delivery systems, genome editing efficiency, and safety evaluation for therapeutic applications. Accelerates the development of genome editing tools, improves editing specificity and delivery efficiency, supports off-target analysis, and advances research into potential gene editing therapies for genetic diseases.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Key Takeaways

  • The UK gene editing market is valued at $80.6 million in 2024 and projected to reach $162.1 million by 2029, representing a 15.0% CAGR.
  • The UK's advanced regulatory environment and life sciences infrastructure position it as a leading European hub for gene editing innovation and clinical development.
  • Strong government funding for genomic research and precision medicine initiatives are accelerating commercialization of gene-edited therapies in the UK.
  • The UK gene editing market growth rate of 15.0% significantly exceeds the global average, reflecting concentrated investment and favorable market conditions.

Gene Editing Market Report Scope

Report Metric Details
Base Year 2024
Fastest Growing Segment CROS & CDMOS (End User)
Forecast Period 2024–2029
Growth Rate CAGR of 10.2% from 2024 to 2029
Largest Segment PRODUCTS (Offering)
Market Size Base Year (Billions) ~USD 4.67 (2024)
Revenue Forecast (Billions) ~USD 7.59 (2029)
Segments Covered Offering, Type, Technique, Technology, Application, End User

UK Gene Editing Market Report Segmentation

6 segment dimensions are covered across the global market.

By Offering

  • Products
  • Services

By Type

  • Cell Line Development & Engineering
  • Gene Editing Kits
  • Gene Editing Libraries
  • Gene Editing Reagents
  • Grna Synthesis & Vector Construction
  • Library Construction & Screening
  • Other Services
  • Reagents & Consumables
  • Software & Systems

By Technique

  • Gene Silencing
  • Knock-In
  • Knock-Out
  • Other Techniques

By Technology

  • Antisense
  • Base Editing
  • Crispr
  • Other Technologies
  • Rnai
  • Talens
  • Zfns

By Application

  • Cell Line Engineering
  • Drug Discovery & Development
  • Genome Editing
  • Other Applications

By End User

  • Academic & Research Institutes
  • Cros & Cdmos
  • Other End Users
  • Pharmaceutical & Biotechnology Companies

UK: GENE EDITING SERVICES MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES22.922.425.529.534.139.445.652.915.7
CROS & CDMOS4.64.75.66.789.611.513.719.6
OTHER END USERS12.411.813.114.616.418.420.623.112.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES33.132.236.441.747.854.862.972.414.7
TOTAL73.171.280.692.5106.4122.3140.6162.115

UK: GENE EDITING PRODUCTS MARKET, BY END USER, 2022–2029

Segment20222023202420252026202720282029CAGR (%)
ACADEMIC & RESEARCH INSTITUTES5352.155.562.871.180.591.3103.613.3
CROS & CDMOS23.723.725.629.433.838.844.551.314.9
OTHER END USERS21.820.721.223.125.227.529.932.69
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES70.8697381.992103.4116.213112.4
TOTAL169.3165.4175.3197.1222.1250.1282318.512.7

Target Audience

  • Biotech & Pharma Companies : Gene editing companies and pharmaceutical firms need UK-specific market data to evaluate market entry opportunities, assess competitive dynamics, and develop localized commercialization strategies for the high-growth British market.
  • Investment & Venture Capital Firms : Investors require detailed UK market analysis to identify promising gene editing startups, assess portfolio company growth potential, and make informed funding decisions in one of Europe's most attractive biotech markets.
  • Healthcare & NHS Decision Makers : NHS commissioners, hospital trusts, and healthcare administrators need market intelligence to evaluate gene editing therapy adoption, budget planning, and integration into treatment pathways for genetic disorders.
  • Research Institutions & Universities : Academic researchers and university technology transfer offices require market data to understand commercialization opportunities, identify industry partnerships, and secure funding for gene editing research programs in the UK.
  • Regulatory & Policy Advisors : Regulatory consultants, policy makers, and compliance professionals need UK-specific market insights to navigate MHRA requirements, inform policy development, and advise clients on the evolving gene editing regulatory landscape.

Key Companies in the UK Gene Editing Market

CompanyHQOwnershipStrongest segments
EPPENDORF AGGermanyPrivate CompanyLiquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors),
ILLUMINA INCUnited StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
CALYXTUnited StatesPublic CompanyRTDS / Trait Machine platform services,Licensed gene-edited traits (royalties and access fees),Collaborative R&D and proof-of-concept projects,
MAXCYTE, INCUnited StatesPublic CompanyExPERT GTx and VLx (therapeutic-scale instruments),ExPERT STx and ATx (discovery and development instruments),Disposable processing assemblies and consumables,
BECKMAN COULTERUnited StatesPrivate CompanyClinical diagnostics analyzers and reagents (chemistry, immunoassay, hematology, urinalysis, hemostasis, clinical flow cytometry),Research and discovery systems (flow cytometry, centrifugation, liquid handling, genomics and single-cell tools),Industrial and particle characterization instruments,
TAKEDA PHARMACEUTICAL COMPANYJapanPublic CompanyGastroenterology (Entyvio, Takecab/Vocinti, EOHILIA),Rare Diseases & Plasma-Derived Therapies (Takhzyro, Advate, ADZYNMA, Gammagard, Hyqvia, Cuvitru, Flexbumin),Oncology (Adcetris, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, Leuplin/Enantone),
DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and single-use solutions),Life Sciences (tools, genomics, and imaging),Diagnostics (clinical instruments and consumables),
REVVITY, INC.United StatesPublic CompanyDiagnostics assays and instruments (prenatal, neonatal, infectious disease, autoimmunity),Life science reagents and consumables (immunology, cell biology, genomics),Instruments, imaging, and detection platforms,
THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO/testing services),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, specialty gases, equipment),
GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
LONZASwitzerlandPublic CompanyIntegrated Biologics,Advanced Synthesis (small molecules, ADCs, HPAPIs),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
SANGAMO THERAPEUTICSUnited StatesPublic CompanyHemophilia A gene therapy collaborations (SB-525 / giroctocogene fitelparvovec),Fabry and other AAV gene therapy programs (ST-920 and related),Genetically modified cell therapy (TX200, kidney transplant),
PRECISION BIOSCIENCESUnited StatesPublic CompanyARCUS platform collaborations and licensing,In vivo HBV and liver disease programs (PBGENE-HBV, iECURE-OTC),Neuromuscular and mitochondrial programs (PBGENE-DMD, PBGENE-3243),
CELLECTIS S.A.FrancePublic CompanyAllogeneic CAR-T for hematologic malignancies (BALLI-01, NatHaLi-01, ALPHA3),Gene therapy and non-hematologic oncology (TRAVERSE, Melanoma, other gene-editing programs),Platform technologies, collaborations, and other R&D-related revenue,
REGENERON PHARMACEUTICALS, INC.United StatesPublic CompanyEYLEA franchise (incl. 8 mg),Dupixent (atopic dermatitis, asthma, other type 2 diseases),Oncology (Libtayo and emerging bispecifics),
TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (COVID-19 and related),

EPPENDORF AG

Eppendorf AG is a German private company founded in 1945 that employs 4,358 people. The company specializes in laboratory equipment and life sciences solutions.

ILLUMINA INC

Illumina Inc. is a publicly traded U.S. company founded in 1998 with 8,625 employees. It is a leading provider of DNA sequencing and genetic analysis technologies.

CALYXT

Calyxt is a publicly traded U.S. company founded in 2010 with 118 employees. The company focuses on plant biotechnology and gene-edited crop development.

MAXCYTE, INC

MaxCyte, Inc. is a publicly traded U.S. company founded in 1998 with 91 employees. It develops cell engineering technologies for therapeutic applications.

BECKMAN COULTER

Beckman Coulter is a private U.S. company founded in 1935 with 11,900 employees. It manufactures laboratory instruments and diagnostic equipment for life sciences research.

TAKEDA PHARMACEUTICAL COMPANY

Takeda Pharmaceutical Company is a publicly traded Japanese pharmaceutical company founded in 1781 with 47,029 employees. It is one of the world's largest pharmaceutical manufacturers.

DANAHER CORPORATION

Danaher Corporation is a publicly traded U.S. company founded in 1969 with 59,000 employees. It operates a diversified portfolio of businesses in diagnostics, life sciences, and environmental solutions.

REVVITY, INC.

Revvity, Inc. is a publicly traded U.S. company founded in 1937 with 11,000 employees. It provides analytical technologies and solutions for life sciences and diagnostics.

THERMO FISHER SCIENTIFIC INC.

Thermo Fisher Scientific Inc. is a publicly traded U.S. company founded in 1956 with 125,000 employees. It is a global leader in serving science with laboratory equipment, reagents, and analytical instruments.

MERCK KGAA

Merck KGaA is a publicly traded German company founded in 1668 with 59,077 employees. It operates in pharmaceuticals, life sciences, and performance materials sectors.

GENSCRIPT

GenScript is a publicly traded company based in Hong Kong, founded in 2002 with 6,165 employees. It provides biotechnology services including gene synthesis, protein production, and antibody development.

AGILENT TECHNOLOGIES, INC.

Agilent Technologies, Inc. is a publicly traded U.S. company founded in 1999 with 18,000 employees. It manufactures analytical instruments and laboratory equipment for life sciences and diagnostics.

LONZA

Lonza is a publicly traded Swiss company founded in 1897 with 20,000 employees. It provides contract manufacturing and life sciences solutions for pharmaceuticals and biotechnology.

SANGAMO THERAPEUTICS

Sangamo Therapeutics is a publicly traded U.S. company founded in 1995 with 142 employees. It develops gene therapy and cell therapy treatments using zinc finger protein technology.

PRECISION BIOSCIENCES

Precision Biosciences is a publicly traded U.S. company founded in 2006 with 66 employees. It develops gene-editing therapies using its proprietary genome editing platform.

CELLECTIS S.A.

Cellectis S.A. is a publicly traded French company founded in 1999 with 227 employees. It develops immunotherapy treatments using gene-edited cell technologies.

REGENERON PHARMACEUTICALS, INC.

Regeneron Pharmaceuticals, Inc. is a publicly traded U.S. company founded in 1988 with 15,343 employees. It discovers, develops, and commercializes medicines for serious medical conditions.

TAKARA BIO INC.

Takara Bio Inc. is a private Japanese company founded in 2002 with 1,779 employees. It develops and manufactures biotechnology products and services for life sciences research.

Reasons to Buy this Report

  • Market Size & Growth Validation : Obtain precise UK market valuation ($80.6M in 2024) and verified forecast data ($162.1M by 2029) to support investment decisions, business planning, and competitive positioning in the high-growth UK gene editing sector.
  • Regulatory & Reimbursement Insights : Understand the UK's unique regulatory pathways, MHRA approval processes, and NHS commissioning frameworks specific to gene editing therapies. Critical intelligence for market entry strategy and commercialization planning.
  • Competitive Landscape Analysis : Identify key players, emerging startups, and research institutions driving innovation in the UK market. Benchmark your position against competitors and discover partnership and acquisition opportunities within the UK biotech ecosystem.
  • Investment & Funding Opportunities : Access data on UK government funding initiatives, venture capital trends, and private investment patterns in gene editing. Essential for securing funding, identifying investors, and understanding capital allocation priorities in the UK market.
  • Clinical & Commercial Readiness : Evaluate the UK's clinical trial landscape, patient populations, and healthcare infrastructure readiness for gene editing therapies. Assess market maturity and identify optimal timing for product launches and expansion strategies.

Frequently asked questions

What is the current size of the UK gene editing market?

The UK gene editing market is valued at $80.6 million in 2024 and is projected to grow to $162.1 million by 2029.

What is the growth rate of the UK gene editing market?

The UK gene editing market is growing at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2029.

What factors are driving growth in the UK gene editing market?

Key drivers include the UK's advanced healthcare infrastructure, strong regulatory framework, substantial government funding for genomic research, and a robust clinical trial ecosystem supporting gene therapy development.

How does the UK gene editing market compare to global trends?

The UK's 15.0% CAGR significantly outpaces the global gene editing market CAGR of 10.2%, reflecting the UK's position as a leading innovation center in Europe.

What gene editing technologies are most prevalent in the UK market?

The UK market encompasses CRISPR-Cas9, base editing, prime editing, and other advanced molecular tools used across therapeutic development and research applications.

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the gene editing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used primarily to identify and gather information for this extensive, technical, market-oriented, and commercial study. The secondary sources referred to for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global gene editing market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Gene Editing Market 
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global gene editing market size was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:

Gene Editing Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

Gene editing refers to technologies used to modify, insert, delete, or regulate specific DNA sequences in cells and organisms. These technologies enable targeted genetic modifications through approaches such as CRISPR-Cas, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), base editing, and other genome engineering techniques. The gene editing market includes products such as reagents & consumables and software & systems, as well as specialized services such as cell line development & characterization, gRNA synthesis & vector construction, and library construction & screening. These products and services are widely used in cell line engineering, genome editing, drug discovery and development, and genetic research. They also support applications in biotechnology, biopharmaceutical production, and therapeutic development. Rising investment in genetic research, advances in genome-editing technologies, and the growing adoption of precision medicine are driving demand for gene editing products and services across pharmaceutical, biotechnology, and academic research institutions.

Key Stakeholders

  • Academic Research Institutes
  • Raw Materials Manufacturers & Distributors
  • Contract Research Organizations (CROs)
  • Service Providers
  • Market Research and Consulting Firms
  • Pharmaceutical & Biotechnology Companies
  • Regulatory Agencies
  • Venture Capitalists
  • Government Organizations
  • Private Research Firms
  • Contract Development and Manufacturing Organizations (CDMOs)

Report Objectives

  • To define, describe, and forecast the gene editing market by product & service, technology, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall gene editing market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil and the Rest of Latin America), the Middle East (GCC Countries and the Rest of the Middle East), and Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

Based on the market data, MarketsandMarkets offers customizations to meet the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the market in the Rest of Europe, by country
  • Further breakdown of the market in the Rest of Asia Pacific, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Cross-segment analysis

 

Get the Full Gene Editing Market Report

Full forecast, segment splits, and company analysis for all Gene Editing Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status